Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NGEN
STRONG SELLREMOVENervGen Pharma Corp. · Healthcare · Canada · $244M · Avg Vol: $3M/d
NervGen Pharma is a clinical-stage biotech company. While its spinal cord injury therapeutics are interesting, it is a binary, pre-revenue R&D story that does not fit our mandate of owning high-ROIC, cash-generating compounders.
COMPANY DESCRIPTION
NervGen Pharma Corp. is a clinical-stage biotechnology company developing a novel therapeutic to promote nervous system repair and regeneration, primarily for spinal cord injury. It focuses on a challenging and underserved area of neuroregeneration, with a unique approach to blocking protein tyrosine phosphatase sigma (PTPσ). NervGen is a clinical-stage biotech firm targeting a high unmet medical need with a potentially transformative therapy for neurological damage.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — |
| EPS | -0.32 | -0.28 | -0.27 | -0.25 | -0.43 | — |
| Shares | 46.2M | 58.8M | 59.6M | 70.3M | 79.6M | +72.4% |
| Debt | 0 | 0.2M | 0.1M | 74,528 | 5,906 | -69.1% |
| Equity | 16.8M | 9.5M | -1.4M | 1.8M | 2.5M | -38.2% |
| Op CF | -8.3M | -12.6M | -8.0M | -11.9M | -13.8M | — |
| Inv CF | -45,085 | -14,895 | -97,995 | 41,550 | 71,228 | — |
| Fin CF | 19.6M | 16.0M | 0.5M | 16.0M | 16.8M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NGEN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NGEN | NervGen Pharma Corp.(you) | $244M | 1 | STRONG SELL |
| HELP | Cybin D/B/A Helus Pharma | $245M | 6 | STRONG SELL |
| MIST | Milestone Pharmaceuticals Inc. | $161M | 1 | STRONG SELL |
| ENGN | enGene Therapeutics Inc. | $114M | 8 | STRONG SELL |
| MSLE | Satellos Bioscience Inc. | $119M | 10 | STRONG SELL |
| PMN | ProMIS Neurosciences, Inc. | $97M | 15 | STRONG SELL |
| QNTM.CN | Quantum BioPharma Ltd. | $45M | 2 | STRONG SELL |
| EPRX | Eupraxia Pharmaceuticals Inc. | $425M | 25 | SELL |
| OBI.L | Ondine Biomedical Inc. | $101M | 20 | SELL |
| EDSA | Edesa Biotech, Inc. | $61M | 17 | STRONG SELL |
Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 35.6%